Kinetic Modeling of DUSP Regulation in Herceptin-Resistant HER2-Positive Breast Cancer

Background: HER2 (human epidermal growth factor 2)-positive breast cancer is an aggressive type of breast cancer characterized by the overexpression of the receptor-type protein tyrosine kinase HER2 or amplification of the HER2 gene. It is commonly treated by the drug trastuzumab (Herceptin), but re...

Descripción completa

Detalles Bibliográficos
Autores principales: Buiga, Petronela, Elson, Ari, Tabernero, Lydia, Schwartz, Jean-Marc
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2019
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6723192/
https://www.ncbi.nlm.nih.gov/pubmed/31357550
http://dx.doi.org/10.3390/genes10080568

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6723192/
https://www.ncbi.nlm.nih.gov/pubmed/31357550
http://dx.doi.org/10.3390/genes10080568

Ejemplares similares